Molecular Pathology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martinez, A
Right arrow Articles by Latif, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martinez, A
Right arrow Articles by Latif, F
J Clin Pathol: Mol Pathol 2001; 54:300-306
© 2001 Journal of Clinical Pathology

Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features

A Martinez, R A Walker, J A Shaw, S J Dearing, E R Maher and F Latif

Section of Medical and Molecular Genetics, Department of Paediatrics and Child Health, University of Birmingham, The Medical School, Edgbaston, Birmingham B15 2TT, UK
Breast Cancer Research Unit, University Of Leicester, Clinical Sciences, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK

Correspondence: Dr Latif flatif{at}hgmp.mrc.ac.uk

Aims—Chromosome 3p allele loss is a frequent event in many common sporadic cancers including lung, breast, kidney, ovarian, and head and neck cancer. To analyse the extent and frequency of 3p allelic losses in T1N0 and T1N1 invasive sporadic breast cancer, 19 microsatellite markers spread along 3p were analysed in 40 such breast carcinomas with known clinicopathological parameters.

Methods—Loss of heterozygosity analysis was carried out using 3p microsatellite markers that were non-randomly distributed and chosen to represent regions that show hemizygous and/or homozygous losses in lung cancer (lung cancer tumour suppressor gene region 1 ( LCTSGR1) at 3p21.3 and LCTSGR2 at 3p12), and regions demonstrating suppression of tumorigenicity in breast, kidney, lung, and ovarian cancer.

Results—Allelic loss was seen at one or more loci in 22 of these clinically early stage sporadic breast tumours, but none had complete 3p allele loss. Several regions with non-overlapping deletions were defined, namely: (1) 18 tumours showed loss at 3p21–22, a physical distance of 12 Mb; (2) 11 tumours showed loss at 3p12 within a physical distance of 1 Mb, this region is contained within LCTSGR2; (3) six tumours showed loss at 3p25–24, including the von Hippel-Lindau (VHL) locus; (4) five tumours showed loss at 3p14.2, including the fragile histidine triad (FHIT) locus.

Conclusions—This is the largest study to date defining the extent and range of 3p allelic losses in early stage invasive breast cancer and the results indicate that region 3p21–22 containing LCTSGR1 and a region at 3p12 within LCTSGR2 are the most frequent sites of 3p allelic loss in these breast carcinomas. This suggests that tumour suppressor genes located in these regions may play important roles in the development of breast cancer. There was an association between increasing 3p allelic loss and increasing tumour grade and loss of progesterone (p = 0.0098) and oestrogen (p = 0.0472) receptor expression, indicating a link between 3p allelic loss and the regulation of differentiation.

Key Words: chromosome 3p • tumour suppressor genes • early invasive breast cancer




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. B. Fox, P. Brown, C. Han, S. Ashe, R. D. Leek, A. L. Harris, and A. H. Banham
Expression of the Forkhead Transcription Factor FOXP1 Is Associated with Estrogen Receptor {alpha} and Improved Survival in Primary Human Breast Carcinomas
Clin. Cancer Res., May 15, 2004; 10(10): 3521 - 3527.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Porter, S. D. Scott, E. M. Sassoon, M. R. Williams, J. L. Jones, A. C. Girling, R. Y. Ball, and D. R. Edwards
Dysregulated Expression of Adamalysin-Thrombospondin Genes in Human Breast Carcinoma
Clin. Cancer Res., April 1, 2004; 10(7): 2429 - 2440.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Agathanggelou, I. Bieche, J. Ahmed-Choudhury, B. Nicke, R. Dammann, S. Baksh, B. Gao, J. D. Minna, J. Downward, E. R. Maher, et al.
Identification of Novel Gene Expression Targets for the Ras Association Domain Family 1 (RASSF1A) Tumor Suppressor Gene in Non-Small Cell Lung Cancer and Neuroblastoma
Cancer Res., September 1, 2003; 63(17): 5344 - 5351.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. J. Hu and A. M. Diamond
Role of Glutathione Peroxidase 1 in Breast Cancer: Loss of Heterozygosity and Allelic Differences in the Response to Selenium
Cancer Res., June 15, 2003; 63(12): 3347 - 3351.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Molecular Pathology Journal of Clinical Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2001 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.